Prelude Therapeutics
PRLD
54 hedge funds and large institutions have $180M invested in Prelude Therapeutics in 2023 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 14 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 15
5% less capital invested
Capital invested by funds: $188M → $180M (-$8.61M)
8% less funds holding
Funds holding: 59 → 54 (-5)
19.78% less ownership
Funds ownership: 85.5% → 65.72% (-20%)
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$4.26M |
| 2 |
Millennium Management
New York
|
+$529K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$516K |
| 4 |
Morgan Stanley
New York
|
+$315K |
| 5 |
Jane Street
New York
|
+$291K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$1.09M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$791K |
| 3 |
NYLIM
New York Life Investment Management
New York
|
-$495K |
| 4 |
Barclays
London,
United Kingdom
|
-$491K |
| 5 |
CANY
Caxton Associates (New York)
New York
|
-$395K |
PRLD Hedge Fund Activity: Q1 2023 in Review
54 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q1 2023, worth a combined $180M — down 4.6% from $188M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of PRLD and 9 opened new positions — a net loss of 5 holders — while 15 trimmed existing stakes and 15 added.
The largest buyer was Boxer Capital, opening a new position worth an estimated $4.26M. The largest seller was Candriam SCA, exiting entirely with an estimated $1.09M sold.
- 54 institutional investors held Prelude Therapeutics (PRLD) as of Q1 2023, down from 59 in Q4 2022.
- Funds reported $180M of Prelude Therapeutics stock for Q1 2023, down 4.6% quarter-over-quarter.
- 9 funds opened new Prelude Therapeutics positions in Q1 2023 and 14 closed out, a net change of -5 holders.
- The largest Prelude Therapeutics buyer in Q1 2023 was Boxer Capital, an estimated $4.26M added.
- The largest Prelude Therapeutics seller in Q1 2023 was Candriam SCA, an estimated $1.09M sold.
Based on aggregated 13F filings for Q1 2023.